| News
Kinarus and Noorik awarded federal grants
13.12.2021
The Basel-based biopharmaceutical companies Kinarus and Noorik have been awarded federal grants for their clinical trials investigating drug candidates to combat Covid-19. The drugs are likely to be available by the end of 2022. In total, the Federal Council has agreed development contracts with four Swiss firms.

The two Basel-based biopharmaceutical firms Kinarus and Noorik have been included in a funding program for Covid-19 drugs operated by the Federal Council, the Swiss federal government. According to a press release, the Federal Council is supporting the development of new drugs to the tune of 27 million Swiss francs. In return, the Federal Council will receive a right of first refusal for these drugs, which are likely to be ready by the end of 2022. Similar contracts have also been signed with Memo Therapeutics from Schlieren in the canton of Zurich and GeNeuro based in Plan-les-Ouates in the canton of Geneva.
The investment as part of the federal program for the promotion of Covid-19 drugs in an unspecified amount will facilitate the acceleration of the clinical development of ambrisetan, according to a press release issued by Noorik Biopharmaceuticals, which is based in Basel. The main objective of the ongoing study is to determine whether the vasodilator ambrisetan is able to prevent the progression of respiratory failure in hospitalized Covid-19 patients, which in turn could reduce the need for mechanical ventilation. The contract agreed with the Federal Council should “hopefully make this therapy broadly available as soon as possible”, explains Elmar Schnee, Chairman of the Board of Directors of Noorik, in the company’s press release.
At present, Kinarus AG is carrying out two clinical trials. The first deals with hospitalized Covid-19 patients, while the other is focused on people with mild to moderate Covid-19 symptoms. The funding of 7 million Swiss francs from the federal support program will serve to “rapidly advance” both clinical trials, the company based at Technologiepark Basel writes in its own press release. “We believe that KIN001 has the potential to be an effective treatment option in the fight against Covid-19”, explains Matthew Wright, COO and Head of Research at Kinarus, before adding: “This grant award is an exceptional validation of our COVID-19 program at Kinarus”.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
Evolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...
Read MoreRecord figure for startups in the Basel Area
Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...
Read MoreNoema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....
Read MoreWhy CDMO companies choose the Basel Area as their location
Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...
Read MoreBasel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...
Read MoreAriceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...
Read More